U.S. FDA authorizes Pfizer COVID-19 booster for children ages 5 to 11

LOS ANGELES, May 17 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Tuesday granted emergency use authorization for a booster dose of the Pfizer-BioNTech COVID-19 vaccine for children 5 through 11 years of age at least five months after completion of the primary vaccine series.

On Jan. 3, the FDA authorized the use of a single booster dose of the Pfizer-BioNTech COVID-19 vaccine for individuals 12 through 15 years of age after completion of primary vaccination.